Laboratory of Translational Genomics

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Subject wise Global Events

Laboratory of Translational Genomics

The Laboratory of Translational Genomics (LTG) conducts studies on germline and somatic genetics of cancer, and analyses on particular regions of the genome conclusively identified in cancer-specific genome-wide association studies (GWAS) and linkage studies in high-risk families.

Research Mission
LTG's mission is to understand the contribution of germline and somatic genetic variation to cancer etiology and outcomes. Its primary goals are to investigate regions of genetic variation by: Detecting cancer susceptibility alleles Fine mapping susceptibility alleles using sequence analysis and imputation from public databases Prioritizing variants for follow-up studies through bioinformatic analysis of candidate variants Deciphering the biological mechanisms underlying susceptibility alleles through laboratory investigation Essential to the mission of the Laboratory is a close collaboration with the NCI-Frederick Cancer Genomics Research Laboratory (CGR). Formerly known as the Core Genotyping Facility (CGF), this laboratory designs and conducts high throughput sequencing, genotyping, and analysis in support of large scale epidemiologic studies.LTG works closely with the NCI CGR. CGR designs and conducts high throughput sequencing and genotyping in support of large-scale epidemiologic studies within the Division of Cancer Epidemiology and Genetics. CGR is also involved in the development of powerful bioinformatics tools that handle high volume genotype data generated from GWAS.
Collaborations and partnerships play a pivotal role in the next wave of genome-wide association studies. Data pooling has become essential in order to achieve the statistical power necessary to detect associations between genomic variants and a variety of health outcomes. High-density chips and emerging technologies now allow the genotyping of millions of SNPs across the genome. Partnerships between the LTG and numerous NCI grantee research organizations are underway, allowing investigation into carcinogenic pathways and gene-environment interactions.